1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Pain: Executive Summary

• 2.1 Substantial Unmet Needs Remain in Core Therapy Types
• 2.2 Highly Diversified Range of Innovative Programs in the Early Pipeline

3 Introduction

• 3.1 Catalyst
• 3.2 Related Reports

4 Disease Overview

• 4.1 Etiology and Pathophysiology
• 4.2 Classification
• 4.3 Sustained Innovation in Pain
• 4.4 Epidemiology for Pain
• 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

• 5.1 Overview
• 5.2 Pipeline by Stage of Development and Molecule Type
• 5.3 Pipeline by Molecular Target
• 5.4 Comparative Distribution of Programs Between Pain Market and Pipeline by Therapeutic Target Family
• 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
• 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline

6 First-in-Class Molecular Target Evaluation

• 6.1 Overview
• 6.2 Pipeline Programs Targeting Neurotensin Receptor 1
• 6.3 Pipeline Programs Targeting Matrix Metalloproteinase-9/2
• 6.4 Pipeline Programs Targeting Beta Nerve Growth Factor
• 6.5 Pipeline Programs Targeting Pituitary Adenylate Cyclase-Activating Polypeptide Type I Receptor
• 6.6 Pipeline Programs Targeting Interleukin-1 Receptor Type 2
• 6.7 Pipeline Programs Targeting Metabotropic Glutamate Receptor 7
• 6.8 Pipeline Programs Targeting Transient Receptor Potential Vanilloid Type 4
• 6.9 Pipeline Programs Targeting P2X Purinoceptor 7
• 6.10 Pipeline Programs Targeting Potassium Channel Subfamily K Member 2

7 Key Players and Deals

• 7.1 Overview

8 Appendix

• 8.1 Bibliography
• 8.2 Abbreviations
• 8.3 Methodology
• 8.4 About the Authors
• 8.5 About GlobalData
• 8.6 Contact Us

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Summary

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes-particularly neuropathic pain-do not respond well to existing therapies. This report assesses first-in-class innovation across the pain pipeline.

Scope

- There are 909 pipeline programs in active development for pain. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
- The market for pain treatment is heavily saturated. Which drug classes are used to treat pain? How do the drug classes in the market compare with those in the pipelines?
- Which molecular target classes are prominently represented in the first-in-class pain pipelines? Which first-in-class targets have been identified as most promising for the treatment of pain? Which first-in-class products have prior deal involvement?

Reasons to buy

- Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology for major pain subtypes.
- Visualize the composition of the pain market in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze and compare the pain pipeline and stratify by stage of development, molecule type, and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
- Recognize commercial opportunities by identifying first-in-class pipeline products for pain that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class pain products.